Robert Carnahan Archives
Pandemic leads to broader use of monoclonal antibodies
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC
Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
‘DNA’ podcast Season 2 explores COVID, science and trust in communities
Aug. 23, 2021—Listen to Episode 1, Blueprint for a Pandemic-Ready Society, and subscribe on your favorite platform. The first episode of the second season of Vanderbilt University Medical Center’s original podcast series, Vanderbilt Health DNA: Discoveries in Action, tackles bold questions and issues pushed to the surface by COVID-19. This season, the award-winning 10-episode series delves into...
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
Aug. 20, 2021—A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
Monoclonal antibody “cocktail” blocks COVID-19 variants: study
Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments
Apr. 8, 2020—Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Researchers developing potential coronavirus antibody therapies
Mar. 23, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Carnahan named associate director of Vaccine Center
Feb. 6, 2020—Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.
VUMC-led team ‘sprints’ to develop Zika virus treatment
Apr. 11, 2019—In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.